Signature Estate & Investment Advisors LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 10.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 4,210 shares of the company’s stock after purchasing an additional 413 shares during the period. Signature Estate & Investment Advisors LLC’s holdings in Johnson & Johnson were worth $662,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Newfound Research LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $28,000. Essex Investment Management Co. LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $37,000. Crewe Advisors LLC lifted its position in shares of Johnson & Johnson by 909.1% during the 3rd quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock worth $50,000 after buying an additional 300 shares in the last quarter. Dimension Capital Management LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $53,000. Finally, IMA Wealth Inc. lifted its position in shares of Johnson & Johnson by 26.8% during the 3rd quarter. IMA Wealth Inc. now owns 478 shares of the company’s stock worth $71,000 after buying an additional 101 shares in the last quarter. 61.26% of the stock is currently owned by hedge funds and other institutional investors.

In related news, COO Michael E. Sneed sold 54,662 shares of the company’s stock in a transaction on Wednesday, December 9th. The shares were sold at an average price of $152.93, for a total value of $8,359,459.66. Following the completion of the transaction, the chief operating officer now directly owns 110,741 shares in the company, valued at $16,935,621.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.27% of the stock is currently owned by insiders.

JNJ has been the topic of several recent analyst reports. Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a research report on Friday, November 20th. BidaskClub raised shares of Johnson & Johnson from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 6th. Cantor Fitzgerald lifted their price target on shares of Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $170.00 to $178.00 and gave the stock an “overweight” rating in a report on Tuesday, December 15th. Finally, Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a report on Wednesday, October 14th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $165.50.

Shares of NYSE:JNJ opened at $157.89 on Thursday. Johnson & Johnson has a 52-week low of $109.16 and a 52-week high of $161.32. The firm has a fifty day moving average of $152.86 and a 200 day moving average of $148.31. The firm has a market capitalization of $415.65 billion, a PE ratio of 24.83, a price-to-earnings-growth ratio of 3.30 and a beta of 0.68. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.22. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The company had revenue of $21.08 billion during the quarter, compared to analyst estimates of $20.15 billion. During the same period in the previous year, the business earned $2.12 earnings per share. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. On average, sell-side analysts forecast that Johnson & Johnson will post 7.99 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 9th. Investors of record on Tuesday, February 23rd will be given a $1.01 dividend. The ex-dividend date is Monday, February 22nd. This represents a $4.04 annualized dividend and a yield of 2.56%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: Bond

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.